Suggested remit: To appraise the clinical and cost effectiveness of masitinib with riluzole within its marketing authorisation for treating amyotrophic lateral sclerosis in adults.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6257
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email [email protected]
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 19 January 2024 - 16 February 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6257 |
| 06 February 2024 | The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of Technology Appraisals masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal. Following an update from the company that market masitinib, NICE will stop the scope consultation and rearrange the scoping exercise for a later date, this is whilst the company confirm their regulatory filing plans. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties if the situation changes. |
| 19 January 2024 | In progress. Scoping commencing |
| 16 June 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual